Centers for Advanced Research

APDA Centers for Advanced Research received $800,000 in funding in 2016.

The Centers support large research programs which include: research trainees; fellowship programs; early stage discovery programs and later stage clinical translation. These Centers facilitate research which is at the forefront investigations in the causes, treatments and ultimately finding the cure(s) for Parkinson’s disease.


University of Alabama at Birmingham, School of Medicine

David G. Standaert, MD, PhD, Director


APDA funding supports:

  • Inflammation in PD
  • 5,054 patient visits per year
  • Deep Brain Stimulation (DBS) Program
  • 24 peer-reviewed manuscripts


David Geffen School of Medicine at UCLA

Marie-Francoise Chesselet, MD, PhD, Director


APDA funding supports:

  • Epidemiological studies in humans
  • Genetic & molecular studies in model organisms
  • Preclinical assessment of investigational therapies
  • Approximately 1,000 patient visits per year


Emory University School of Medicine

Mahlon R. DeLong, MD, Director


APDA funding supports:

  • Functional surgery
  • Research trainees
  • Two day intensive evaluation of Parkinson’s Disease patients
  • Approximately 10,000 total patients seen each year


Boston University School of Medicine

Marie Hélène Saint-Hilaire, MD, FRCP (C), Director


APDA funding supports:

  • Biomarker Studies
  • Studies of Non-Motor Symptoms
  • Studies of Self-Management strategies in PD
  • Active Clinical Trials Program
  • 3500 PD Patient visits per year – Deep Brain Stimulation Program


Washington University School of Medicine

Joel S. Perlmutter, MD, Director


APDA funding supports:

  • Provided pilot data for six currently funded NIH RO1 grants
  • Biomarkers for Parkinson’s Disease & cognitive impairment occurrence
  • Exercise, emphasizing gait and balance
  • More than 4,000 Parkinson’s Disease patient visits


Rutgers Robert Wood Johnson Medical School

Lawrence I. Golbe, MD, Director


APDA funding supports:

  • Neuroprotective activity of a non-caffeine component of coffee
  • The role of TG2 in the pathologic aggregation of alpha-synuclein
  • L-dopa induced dyskinesia Atypical parkinsonism, progressive supranuclear palsy
  • 999 patient visits per year


University of Pittsburgh Medical Center

J. Timothy Greenamyre, MD, PhD, Director


APDA funding supports:

  • Fellowship program in movement disorders
  • Intraoperative MRI guided DBS offered
  • Non-motor symptoms study
  • Therapeutic alpha-synuclein knockdown study
  • 1,000 patient visits per year


University of Virginia Health System

Madaline B. Harrison, MD, Director


APDA funding supports:

  • MR guided focused ultrasound projects
  • Genetics and characterization of neuropsychiatric disorders in Parkinson’s Disease
  • Heritability of motor and non-motor symptoms in PD
  • Approximately 857 patient visits per year

Share this page: